MOLECULAR DOCKING STUDIES OF IMIDAZOLE DERIVATIVES AS NEW CLASS OF HIV-1 PROTEASE INHIBITOR

The human immunodeficiency virus (HIV) infects the immune system that leads to immune deficiency. Acquired immunodeficiency syndrome (AIDS) is defined as the most advanced stages of HIV infection. It is defined by the occurrence of any of more than 20 opportunistic infections or HIV-related cancers. According WHO and UNAIDS estimation, 36.7 million people were living with HIV globally by the end of 2015. 2.1 million People became newly infected, and 1.1 million died of HIV-related causes at the same year. HIV-1 protease plays a vital role in the maturation of virus in order to produce the infectious viral particles. In this study, molecular docking was performed on various imidazole derivatives by Autodock 4.2 into active sites of HIV-1 protease (PDB ID: 4RVI). Key Words: Human immunodeficiency virus, HIV-1 Protease, 4RVI, Molecular Docking, Imidazole derivatives